

Gregory J Fermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5394020/publications.pdf>

Version: 2024-02-01

69
papers

1,392
citations

471371

17
h-index

360920

35
g-index

70
all docs

70
docs citations

70
times ranked

2050
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. Academic Emergency Medicine, 2016, 23, 223-242.	0.8	230
2	The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. Molecular Psychiatry, 2020, 25, 283-296.	4.1	92
3	Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events. JACC: Heart Failure, 2015, 3, 737-747.	1.9	83
4	Point of care testing in the emergency department. Journal of Emergency Medicine, 2002, 22, 393-404.	0.3	80
5	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure—A Pilot Study (PRONTO). American Heart Journal, 2014, 167, 529-536.	1.2	80
6	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	0.7	73
7	Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers, 2012, 17, 706-713.	0.9	45
8	Elevated urinary neutrophil gelatinase-associated lipocalin after acute heart failure treatment is associated with worsening renal function and adverse events. European Journal of Heart Failure, 2012, 14, 1020-1029.	2.9	42
9	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions—A Consensus Document from the <sc>SAEM</sc>/<sc>HFSA</sc> Acute Heart Failure Working Group. Academic Emergency Medicine, 2015, 22, 94-112.	0.8	41
10	Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. American Journal of Emergency Medicine, 2016, 34, 257-262.	0.7	36
11	Multicenter Evaluation of the <sc>YEARS</sc> Criteria in Emergency Department Patients Evaluated for Pulmonary Embolism. Academic Emergency Medicine, 2018, 25, 987-994.	0.8	35
12	Risk stratification in acute heart failure: Rationale and design of the STRATIFY and DECIDE studies. American Heart Journal, 2012, 164, 825-834.	1.2	31
13	Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the <sc>EINSTEIN PE</sc> Study. Academic Emergency Medicine, 2015, 22, 299-307.	0.8	31
14	Markers of diuretic resistance in emergency department patients with acute heart failure. International Journal of Emergency Medicine, 2017, 10, 17.	0.6	30
15	Ground Emergency Medical Services Requests for Helicopter Transfer of ST-segment Elevation Myocardial Infarction Patients Decrease Medical Contact to Balloon Times in Rural and Suburban Settings. Academic Emergency Medicine, 2012, 19, 153-160.	0.8	24
16	Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes. Open Biomarkers Journal, 2012, 5, 1-8.	0.1	24
17	External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 769-774.	0.7	19
18	International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thrombosis Research, 2018, 166, 63-70.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>JAMA Cardiology</i> , 2021, 6, 200.	3.0	18
20	Observation Units in the Management of Acute Heart Failure Syndromes. <i>Current Heart Failure Reports</i> , 2010, 7, 125-133.	1.3	17
21	Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	17
22	Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. <i>American Journal of Emergency Medicine</i> , 2018, 36, 396-402.	0.7	17
23	Risk stratification and short-term prognosis in acute heart failure syndromes: A review of novel biomarkers. <i>Biomarkers</i> , 2011, 16, 379-392.	0.9	16
24	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , 2017, 12, e0185022.	1.1	16
25	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 149-157.	1.0	15
26	Socio-demographic and trauma-related predictors of depression within eight weeks of motor vehicle collision in the AURORA study. <i>Psychological Medicine</i> , 2022, 52, 1934-1947.	2.7	15
27	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. <i>Internal and Emergency Medicine</i> , 2017, 12, 311-318.	1.0	14
28	TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial). <i>Circulation: Heart Failure</i> , 2019, 12, e005931.	1.6	14
29	Incremental Benefit of 80-lead Electrocardiogram Body Surface Mapping Over the 12-lead Electrocardiogram in the Detection of Acute Coronary Syndromes in Patients Without ST-segment Elevation Myocardial Infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) Trial. <i>Academic Emergency Medicine</i> , 2010, 17, 932-939.	0.8	13
30	Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. <i>Pharmacotherapy</i> , 2016, 36, 1109-1115.	1.2	13
31	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 830-837.	0.7	13
32	External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches. <i>Thrombosis Journal</i> , 2016, 14, 7.	0.9	11
33	What's Next for Acute Heart Failure Research?. <i>Academic Emergency Medicine</i> , 2018, 25, 85-93.	0.8	11
34	D-dimer levels in VTE patients with distal and proximal clots. <i>American Journal of Emergency Medicine</i> , 2019, 37, 33-37.	0.7	11
35	Unequal but Fair: Incorporating Distributive Justice in Operational Allocation Models. <i>Production and Operations Management</i> , 2021, 30, 2304-2320.	2.1	11
36	Initial Management of Patients with Acute Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 291-301.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	0.8	10
38	Randomized Controlled Noninferiority Trial Comparing Daptomycin to Vancomycin for the Treatment of Complicated Skin and Skin Structure Infections in an Observation Unit. <i>Journal of Emergency Medicine</i> , 2015, 49, 928-936.	0.3	9
39	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1163-1170.	0.7	9
40	Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 1697-1703.	0.9	7
41	Aortic Dissection Detectionâ€Risk Score: A Clinical Decision Rule that Needs Some Parenting. <i>Academic Emergency Medicine</i> , 2018, 26, 695-697.	0.8	7
42	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 513-519.	1.0	6
43	Developing a standardized measurement of alcohol intoxication. <i>American Journal of Emergency Medicine</i> , 2017, 35, 725-730.	0.7	6
44	Highly Elevated Quantitative D-Dimer Assay Values Increase the Likelihood of Venous Thromboembolism. <i>TH Open</i> , 2019, 03, e2-e9.	0.7	6
45	Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA. <i>Advances in Therapy</i> , 2020, 37, 3942-3953.	1.3	6
46	Sexâ€related differences in Dâ€dimer levels for venous thromboembolism screening. <i>Academic Emergency Medicine</i> , 2021, 28, 873-881.	0.8	6
47	External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. <i>BMC Health Services Research</i> , 2016, 16, 610.	0.9	5
48	Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. <i>Thrombosis Research</i> , 2016, 141, 8-10.	0.8	5
49	Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2017, 6, 84.	1.0	5
50	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007956.	0.9	5
51	Early Treatment for Nonâ€STâ€Segment Elevation Acute Coronary Syndrome Is Associated with Appropriate Discharge Care. <i>Clinical Cardiology</i> , 2009, 32, 519-525.	0.7	4
52	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016, 22, 618-627.	0.7	4
53	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. <i>Journal of Health Economics and Outcomes Research</i> , 2019, 6, 84-94.	0.6	4
54	Performance of a body surface mapping system using emergency physician real-time interpretation. <i>American Journal of Emergency Medicine</i> , 2009, 27, 816-822.	0.7	3

#	ARTICLE	IF	CITATIONS
55	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. <i>Internal and Emergency Medicine</i> , 2017, 12, 613-619.	1.0	3
56	External validation of the multivariable "In-hospital Mortality for Pulmonary embolism using Claims data" prediction rule in the Premier Hospital Database. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw046.	1.8	2
57	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. <i>International Journal of Clinical Practice</i> , 2017, 71, e12915.	0.8	2
58	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. <i>Clinical Therapeutics</i> , 2017, 39, 1426-1436.e2.	1.1	2
59	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 37.	0.8	2
60	Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 85-90.	1.1	2
61	Troponin is unrelated to outcomes in heart failure patients discharged from the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12695.	0.4	2
62	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. <i>International Journal of Cardiology</i> , 2016, 222, 846-849.	0.8	1
63	Outcomes related to variation in hospital pulmonary embolus observation stay utilization. <i>Hospital Practice (1995)</i> , 2016, 44, 133-137.	0.5	1
64	Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. <i>Journal of Medical Economics</i> , 2020, 23, 1409-1417.	1.0	1
65	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. <i>Journal of Health Economics and Outcomes Research</i> , 2019, 6, 160-173.	0.6	1
66	In Reply. <i>Academic Emergency Medicine</i> , 2016, 23, 843-843.	0.8	0
67	Observation Unit Admission Inclusion and Exclusion Criteria. <i>Contemporary Cardiology</i> , 2012, , 165-171.	0.0	0
68	Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy. <i>Blood</i> , 2013, 122, 1139-1139.	0.6	0
69	Observation Unit Admission Inclusion and Exclusion Criteria. <i>Contemporary Cardiology</i> , 2017, , 187-195.	0.0	0